Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,142 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05341557RecruitingPhase 1
First-in-human drug study for advanced cancers and lymphoma
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Chaoyang, Beijing MunicipalityAges 18 years+ - NCT05345587Recruiting
Digital monitoring plus proactive medication review during oral cancer treatment
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
Brive-la-GaillardeAges 18 years+ - NCT05350475Recruiting
Prostate cancer radiotherapy with protons versus photons
This trial compares two types of radiation—protons versus photons—for high-risk localized prostate cancer. It aims to see which option works well while causing fewer problems for nearby organs.
Copenhagen, Capital RegionAges 18 years+ - NCT05367778RecruitingPhase 1/Phase 2
Study of HS-10370 for advanced cancers with KRAS G12C
This trial tests HS-10370, a new targeted medicine, in people with advanced solid tumors that cannot be treated with standard options. It focuses on cancers that have a specific change in the KRAS gene (KRAS G12C).
Wuhan, HubeiAges 18 years+ - NCT05367635RecruitingPhase 1
Testing a new drug for advanced stomach cancers with CLDN18.2
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT05417321RecruitingPhase 1/Phase 2
Test of HB0036 for advanced cancers that ran out of options
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Lafayette, IndianaAges 18 years+ - NCT05427383RecruitingPhase 2/Phase 3
KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
BeijingAges 18 years+ - NCT05434234RecruitingPhase 1/Phase 2
Study drug YL201 for advanced solid tumors
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
Fair Oaks, CaliforniaAges 18 years+ - NCT05439993RecruitingPhase 1/Phase 2
Tepotinib plus paclitaxel for MET-altered stomach cancer
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
Gyeonggi-doAges Any age - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT05444270Recruiting
Radiation and medicine for recurrent ovarian cancer
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
SeoulAges 19 years+ - NCT05444088RecruitingPhase 1/Phase 2
Immunotherapy plus targeted drug for advanced liver cancer
This trial tests SHR-8068 combined with adebrelimab and bevacizumab in people with advanced, hard-to-treat liver cancer. It aims to see whether this combination can shrink tumors and improve outcomes after standard treatments don’t work or aren’t an option.
Hefei, AnhuiAges 18–75 - NCT05448547RecruitingPhase 3
Tested curative vs conservative treatment for older men with high-risk prostate cancer
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
CopenhagenAges 75 years+ - NCT05451602RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with RET changes
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
GuangzhouAges 18 years+ - NCT05462496RecruitingPhase 2
Pembrolizumab plus gut microbiome changes after pancreatic chemo
This Phase 2 study tests whether changing the gut microbiome (the gut’s helpful bacteria) and giving pembrolizumab after chemotherapy can improve outcomes for people with operable pancreatic cancer. It aims to see if this approach can boost the immune system after standard treatment and help reduce cancer returning.
New York, New YorkAges 19 years+ - NCT05473624RecruitingPhase 1
Test drug HRS-1167 for advanced cancers that need new options
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
Beijing, Beijing MunicipalityAges 18 years+ - NCT05475015Recruiting
3D MRI scan to assess liver scarring and pressure
This study tests whether a special 3D MRI scan (3D-MRE) can measure liver scarring and the high pressure in the liver called portal hypertension. It may help your team use imaging to understand how severe your liver disease is, especially when a pressure test (HVPG) is being considered.
Shenyang, LiaoningAges 18–75 - NCT05836948RecruitingPhase 1
Testing SHR-9839 for advanced solid tumors
This Phase 1 trial studies SHR-9839, a new injection medicine, for people with advanced solid tumors that can’t be removed by surgery and have returned or stopped responding to standard care. It mainly aims to find a safe dose and see early signs of whether the treatment can work.
Hangzhou, ZhejiangAges 18–70 - NCT05487170RecruitingPhase 1/Phase 2
Early trial of RNK05047 for advanced cancers
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
Atlanta, GeorgiaAges 18 years+ - NCT05529940RecruitingPhase 3
FOLFIRINOX around surgery for resectable pancreatic cancer
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
SeoulAges 19–80
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,142 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.